Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press12510.17650/1726-9776-2013-9-3-64-69PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫPROGNOSTIC FACTORS OF BIOCHEMICAL RELAPSE FREE SURVIVAL FOLLOWING SALVAGE RADIOTHERAPY IN MEN WITH BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMYФАКТОРЫ ПРОГНОЗА БЕЗРЕЦИДИВНОЙ ВЫЖИВАЕМОСТИ ПОСЛЕ СПАСИТЕЛЬНОЙ ЛУЧЕВОЙ ТЕРАПИИ У ПАЦИЕНТОВ С БИОХИМИЧЕСКИМ РЕЦИДИВОМ ПОСЛЕ РАДИКАЛЬНОЙ ПРОСТАТЭКТОМИИDemeshkoP. D.ДемешкоП. Д.
Belarus
pdemeshko@me.comSukonkoO. G.СуконкоО. Г.
Belarus
pdemeshko@me.comKrasnyS. A.КрасныйС. А.
Belarus
pdemeshko@me.comSuslovaV. A.СусловаВ. А.
Belarus
pdemeshko@me.comN.N. Alexandrov National Cancer Center of Belarus, MinskРНПЦ ОМР им. Н.Н. Александрова, Минск300920139364692707201427072014https://oncourology.abvpress.ru/oncur/article/view/125

Purpose. To evaluate influence of clinical, biochemical and histological factors to biochemical relapse free survival (BRFS) following salvage radiotherapy (RT) in men with biochemical recurrence after radical prostatectomy.

Material and methods. 77 patients with newly diagnosed biochemical recurrence (BR) after RPE were included into retrospective study. All of them underwent local salvage RT. Сlinical variables (age, serum prostate-specific antigen [PSA] level and PSA kinetics, time RPE-BR, Gleason grade, stage after RPE and clinical findings) were evaluated using Cox proportional hazards regression analysis.

Results. The median, 1- and 3-year BRFS were 19,9 months, 63,8 ± 6,5 % and 24,7 ± 8,5 % respectively. Significant variables in the multivariable model were age, PSA level before RT, prostatectomy T3b stage, PSA doubling time and positive digital rectal examination findings (p < 0,05). Several clinical parameters help predict the outcomes of men with PSA elevation after radical prostatectomy. These data may be useful in counseling men regarding the timing of administration of adjuvant therapies.

prostate cancerbiochemical recurrencesalvage radiotherapyрак предстательной железыбиохимический рецидивспасительная лучевая терапия1. Partin A.W., Mangold L.A., Lamm D.M. et al. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58(6):843–8.Partin A.W., Mangold L.A., Lamm D.M. et al. Contemporary update of the prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001;58(6):843–8.2. Bill-Axelson A., Holmberg L., Ruutu M. et al. Scandinavian prostate cancer group study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977–84.Bill-Axelson A., Holmberg L., Ruutu M. et al. Scandinavian prostate cancer group study No. 4. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005;352:1977–84.3. Bill-Axelson A., Holmberg L., Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364(18):1708–17.Bill-Axelson A., Holmberg L., Ruutu M. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364(18):1708–17.4. Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–7.Pound C.R., Partin A.W., Eisenberger M.A. et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999;281(17):1591–7.5. Bolla M., van Poppel H., Collette L. et al. European organization for research and treatment of cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485):572–8.Bolla M., van Poppel H., Collette L. et al. European organization for research and treatment of cancer. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366(9485):572–8.6. Stephenson A.J., Shariat S.F., Zelefsky M.J. et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325–32.Stephenson A.J., Shariat S.F., Zelefsky M.J. et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 2004;291:1325–32.7. Bianco F.J., Scardino P.T., Eastham Bianco J.A. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 2005;66:83–94.Bianco F.J., Scardino P.T., Eastham Bianco J.A. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology 2005;66:83–94.8. Stephenson A.J., Slawin K.M. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat Clin Pract Urol 2004;1:90–6.Stephenson A.J., Slawin K.M. The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy. Nat Clin Pract Urol 2004;1:90–6.9. Trock B.J., Han M., Freedland S.J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299(23):2760–9.Trock B.J., Han M., Freedland S.J. et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 2008;299(23):2760–9.10. D’Amico A.V., Chen M.H., Roehl K.A., Catalona W.J. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23:4975–9.D’Amico A.V., Chen M.H., Roehl K.A., Catalona W.J. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005;23:4975–9.11. D’Amico A.V., Moul J.W., Carroll P.R. et al. Surrogate end point for prostate cancerspecific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–83.D’Amico A.V., Moul J.W., Carroll P.R. et al. Surrogate end point for prostate cancerspecific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003;95:1376–83.12. Демешко П.Д., Красный С.А. Факторы прогноза системного прогрессирования рака предстательной железы у пациентов с биохимическим рецидивом после радикальной простатэктомии. Онкоурология 2013;1:24–30.Демешко П.Д., Красный С.А. Факторы прогноза системного прогрессирования рака предстательной железы у пациентов с биохимическим рецидивом после радикальной простатэктомии. Онкоурология 2013;1:24–30.13. Freedland S.J., Humphreys E.B., Mangold L.A. et al. Risk of prostate cancerspecifc mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–9.Freedland S.J., Humphreys E.B., Mangold L.A. et al. Risk of prostate cancerspecifc mortality following biochemical recurrence after radical prostatectomy. JAMA 2005;294:433–9.14. Okotie O.T., Aronson W.J., Wieder J.A. et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004;171 (6, Pt 1):2260–4.Okotie O.T., Aronson W.J., Wieder J.A. et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol 2004;171 (6, Pt 1):2260–4.